Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Care management intervention strategies
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

3 evidence topics · 3 sources

Cardiac monitoring

“Conduct cardiac assessment at least annually” (opens the source at this quote in a new tab)

Adult DMD care and cardiac monitoring

“All patients should have annual cardiologist follow up with assessment of cardiac function by echo or cMRI.” (opens the source at this quote in a new tab)

Caregiver support

“Assist with arranging respite care for caregivers” (opens the source at this quote in a new tab)